Skip to main content
Fig. 10 | BMC Cancer

Fig. 10

From: A potential small-molecule synthetic antilymphangiogenic agent norcantharidin inhibits tumor growth and lymphangiogenesis of human colonic adenocarcinomas through blocking VEGF-A,-C,-D/VEGFR-2,-3 “multi-points priming” mechanisms in vitro and in vivo

Fig. 10

NCTD inhibits the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 proteins/mRNAs of the in-situ colonic xenografts in vivo. a Western-blotting: the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 proteins in NCTD, Sorafenib, or NCTD + Sorafenib group was significantly downregulated as compared to control group (*P < 0.01, #P < 0.001), the expression of these proteins in NCTD + Sorafenib group was significantly lower than those of Sorafenib group or NCTD group (P < 0.05); but there was no difference on the expression of these proteins between NCTD group and Sorafenib group. b Fluorescent quantitative RT-PCR: the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 mRNAs in NCTD, Sorafenib, or NCTD + Sorafenib group was significantly decreased as compared to control group (*P < 0.01, #P < 0.001); whereas the expression of these mRNAs in NCTD + Sorafenib group was significantly lower than those of Sorafenib group or NCTD group (P < 0.05); but no difference on the expression of these mRNAs was observed between NCTD group and Sorafenib group

Back to article page